Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

VRE : 18.93 (+0.05%)
SEM : 16.30 (+0.06%)
DAWN : 21.42 (+0.05%)
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals...

DAWN : 21.42 (+0.05%)
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

DAWN : 21.42 (+0.05%)
TALK : 5.16 (+0.19%)
UNF : 250.00 (+0.56%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--DAWN, SEM, FONAR, and JHG

NEW YORK , March 11, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

JHG : 51.40 (+0.04%)
SEM : 16.30 (+0.06%)
DAWN : 21.42 (+0.05%)
FONR : 18.54 (-0.16%)
Are DAWN and TALK Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

DAWN : 21.42 (+0.05%)
TALK : 5.16 (+0.19%)
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals...

DAWN : 21.42 (+0.05%)
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

DAWN : 21.42 (+0.05%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

NEW YORK , March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions...

DAWN : 21.42 (+0.05%)
DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

DAWN : 21.42 (+0.05%)
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

SURESNES, France and BRISBANE, Calif. , March 6, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq:...

DAWN : 21.42 (+0.05%)

Barchart Exclusives

Arm Is Making ‘Bold Moves’ with New In-House Chips and Wall Street Loves It. Why Needham Says You Should Buy ARM Stock Here.
Arm is suddenly being viewed as more than an IP licensor, as its new AGI CPU and rising AI data center relevance are pushing Wall Street to re-rate the stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.